WMr. Tut - The importance of a talented and connected IR firm is more significant than most retail investors realize. The good ones are capable of delivering very high multiples, significantly higher multiples than the prior "spread the word approach". It is all about spin. There are numerous companies that have never made a profit and likely never will that are trading well above $1, some above $5 and $10 per share. With Scrips' profitability in Q3, as well as probably Q4 and this quarter, with a strong IR firm coupled with an uplisting to a major exchange, ScripsAmerica will exceed the SeeThruEquity target of $1.20 without the RapiMeds pipedream.
I am very glad to have found this company and put a little money into it. It will be nice to see where it is in the next two to three years. If all goes well and the company continues growing net earnings, I would be surprised to see the stock price below $2.50 by the end of 2017.